Company: SION
Filing Date: 2025-01-17
Form Type: S-1
Source: 0001193125-25-008474
Chunk: 143

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-01-17
Form: S-1
Chunk 143
---
 (36,247 | ) |      | $                       | (43,699 | ) |      | $ | (36,068 | ) |
| Net cash (used in) provided by investing activities                   |      |                   | (142,141 | ) |      |   |  20,224 |   |      |                         |  27,352 |   |      |   | (29,263 | ) |
| Net cash provided by financing activities                             |      |                   |  180,375 |   |      |   |      31 |   |      |                         |      31 |   |      |   | 110,855 |   |
| Net (decrease) increase in cash, cash equivalents and restricted cash |      | $                 |   (2,772 | ) |      | $ | (15,992 | ) |      | $                       | (16,316 | ) |      | $ |  45,524 |   |

Operating Activities For the nine months ended September 30, 2024, net cash used in operating activities was $41.0 million primarily due to our net loss of $45.8 million and changes in operating assets and liabilities of $6.2 million, partially offset by $11.0 million of non-cashcharges related to non-cashlicense expense, stock-based compensation, depreciation, non-cashoperating lease expense and amortization of discounts on marketable securities. 103

For the nine months ended September 30, 2023, net cash used in operating activities was
$36.2 million primarily due to our net loss of $35.4 million and changes in our operating assets and liabilities of $3.9 million, partially offset by $3.0 million of non-cash charges
related to stock-based compensation, depreciation and amortization of discounts on marketable securities.

For the year ended December 31,
2023, net cash used in operating activities was $43.7 million primarily due to our net loss of $47.3 million and changes in operating assets and liabilities of $0.8 million, partially offset by $4.4 million of non-cash charges related to stock-based compensation, depreciation, non-cash operating lease expense and amortization of discounts on marketable securities.

For the year ended December 31, 2022, net cash used in operating activities was $36.1 million primarily due to our net loss of
$40.2 million